Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal wom
Fulvestrant in the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: A review. - Abstract - Europe PMC
Breast Cancer Update - Lynn Sage 2001
Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies | Future Medicinal Chemistry
Ribociclib Improves Survival in Advanced Breast Cancer - NCI
Fulvestrant - LiverTox - NCBI Bookshelf
A Review of Fulvestrant in Breast Cancer | SpringerLink
Mode of action of estradiol and fulvestrant. AF1: activation function... | Download Scientific Diagram
Shapiro Lab Research Areas
Figure 2 from ICI 182,780 (Fulvestrant™) – the first oestrogen receptor down-regulator – current clinical data | Semantic Scholar
Frontiers | Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer
The molecular mechanism for the pure steroidal ERα antagonist,... | Download Scientific Diagram
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer | Breast Cancer Research | Full Text
Fulvestrant | SpringerLink
Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer | Journal of Medicinal Chemistry
RESEARCH - JESELSOHN LAB - TRANSLATIONAL BREAST CANCER RESEARCH
Estrogen Receptor Modulator - an overview | ScienceDirect Topics
Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action | British Journal of Cancer
Fulvestrant in advanced breast cancer: evidence to date and place in therapy - Katalin Boér, 2017
Pure Antiestrogens - Selective Estrogen Receptor Modulators. Antonio Cano
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review - Li - 2019 - Cancer Medicine - Wiley Online Library
Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF-1 pathway inhibition in vivo
